BACKGROUND: adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. METHODS: we performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. RESULTS: in MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. CONCLUSION: the presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
RCT Entities:
BACKGROUND: adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. METHODS: we performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfectedpersons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. RESULTS: in MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. CONCLUSION: the presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors: Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga Journal: J Virol Date: 2003-08 Impact factor: 5.103
Authors: Anna R Thorner; Ronald Vogels; Jorn Kaspers; Gerrit J Weverling; Lennart Holterman; Angelique A C Lemckert; Athmanundh Dilraj; Lisa M McNally; Prakash M Jeena; Soren Jepsen; Peter Abbink; Anjali Nanda; Patricia E Swanson; Andrew T Bates; Kara L O'Brien; Menzo J E Havenga; Jaap Goudsmit; Dan H Barouch Journal: J Clin Microbiol Date: 2006-10 Impact factor: 5.948
Authors: Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic Journal: Infect Immun Date: 2008-01-22 Impact factor: 3.441
Authors: Jun Wang; Lisa Thorson; Richard W Stokes; Michael Santosuosso; Kris Huygen; Anna Zganiacz; Mary Hitt; Zhou Xing Journal: J Immunol Date: 2004-11-15 Impact factor: 5.422
Authors: Peter Abbink; Angelique A C Lemckert; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Shirley Smits; Lennart Holterman; Irma Damen; Ronald Vogels; Anna R Thorner; Kara L O'Brien; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch Journal: J Virol Date: 2007-02-28 Impact factor: 5.103
Authors: Mary A Hoelscher; Sanjay Garg; Dinesh S Bangari; Jessica A Belser; Xiuhua Lu; Iain Stephenson; Rick A Bright; Jacqueline M Katz; Suresh K Mittal; Suryaprakash Sambhara Journal: Lancet Date: 2006-02-11 Impact factor: 79.321
Authors: Daniel E Zak; Erica Andersen-Nissen; Eric R Peterson; Alicia Sato; M Kristina Hamilton; Joleen Borgerding; Akshay T Krishnamurty; Joanne T Chang; Devin J Adams; Tiffany R Hensley; Alexander I Salter; Cecilia A Morgan; Ann C Duerr; Stephen C De Rosa; Alan Aderem; M Juliana McElrath Journal: Proc Natl Acad Sci U S A Date: 2012-11-14 Impact factor: 11.205
Authors: Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller Journal: J Virol Date: 2011-12-07 Impact factor: 5.103
Authors: Kathryn E Stephenson; John Hural; Susan P Buchbinder; Faruk Sinangil; Dan H Barouch Journal: J Infect Dis Date: 2012-04-05 Impact factor: 5.226
Authors: Sai V Vemula; Yadvinder S Ahi; Anne-Marie Swaim; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240